Search

Introduction: Antenatal maternal magnesium sulfate (MgSO 4 ) administration is a proven efficacious neuroprotective treatment reducing the risk of cerebral palsy (CP) among infants born preterm. Identification of the neuroprotective component with target plasma concentrations could lead to neonatal treatment with greater efficacy and accessibility., Methods and Analysis: This is a prospective observational cohort study, in three tertiary Australian centres. Participants are preterm infants, irrespective of antenatal MgSO 4 exposure, born in 2013-2020 at 24 +0 to 31 +6 weeks gestation, and followed up to 2 years corrected age (CA) (to September 2023). 1595 participants are required (allowing for 17% deaths/loss to follow-up) to detect a clinically significant reduction (30% relative risk reduction) in CP when sulfate concentration at 7 days of age is 1 SD above the mean.A blood sample is collected on day 7 of age for plasma sulfate and magnesium measurement. In a subset of participants multiple blood and urine samples are collected for pharmacokinetic studies, between days 1-28, and in a further subset mother/infant blood is screened for genetic variants of sulfate transporter genes.The primary outcome is CP. Surviving infants are assessed for high risk of CP at 12-14 weeks CA according to Prechtl's Method to assess General Movements. Follow-up at 2 years CA includes assessments for CP, cognitive, language and motor development, and social/behavioural difficulties.Multivariate analyses will examine the association between day 7 plasma sulfate/magnesium concentrations with adverse neurodevelopmental outcomes. A population pharmacokinetic model for sulfate in the preterm infant will be created using non-linear mixed-effects modelling., Ethics and Dissemination: The study has been approved by Mater Misericordiae Ltd Human Research Ethics Committee (HREC/14/MHS/188). Results will be disseminated in peer-reviewed journal publications, and provided to the funding bodies. Using consumer input, a summary will be prepared for participants and consumer groups., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.)

This study proposed and validated a method integrating in situ hydrotalcite precipitation (Virtual Curtain™ (VC) technology) with bioprocess for treating a cyanide (CN)-augmented (ca. 5 mg-CN L -1 ) sulfate-laden neutral mine drainage, from a waste rock dump (WD2) of an Australian gold mine. Efficacies of various carbon (C) sources (ethanol, lactate, and two natural substrates; Eucalyptus wood sawdust (EW) and Typha biomass (TB)) for promoting microbial reduction in both: CN-augmented WD2 water and VC-treated CN-augmented WD2 water were assessed in a 60-days microcosms study at 30 °C. The microcosms were monitored over time for pH, redox potential, dissolved hydrogen sulfide, chloride, nitrite, nitrate, sulfate, phosphate, biogas production, dissolved organic carbon, total dissolved nitrogen, and dissolved CN. The VC treatment removed a range of metals (Mg, Ni and Zn) and metalloid Se from the CN-augmented WD2 water to below detection. Other elements substantially reduced in concentration included Ba, F, Si and U. However, the VC treatment did not remove substantial nitrate, sulfate or CN. Microcosm trials revealed that the indigenous microbial community in WD2 could effectively denitrify and reduce sulfate, with TB was the most efficient C source for promoting sulfate and CN removal; whereas, EW facilitated only marginally higher sulfate reduction compared with controls. The highest sulfate reduction rate (76 g-SO 4 2- m -3 d -1 ) was achieved with VC-treated water amended with TB, indicating that VC pre-treatment was beneficial. Further, all treatments amended with external C, facilitated 100% removal of dissolved CN after 60 days, whereas only partial (65%) CN removal was recorded in the control. Overall, the proposed integrated method appears a viable option for treating neutral gold mine drainage., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)